POSTERS & PUBLICATIONS
2019
SARA program: preliminary findings from SARA-OBS study and impacts on the SARA-INT study design. Dioh et al. Oral presentation at SCWD conference on cachexia, sarcopenia and muscle wasting. December 6-8th, Berlin, Germany
Abstract published in Journal of Cachexia, Sarcopenia and Muscle
Preclinical characterization of Sarconeos (API BIO101) in Duchenne muscular dystrophy. Latil et al. Poster presentation at the 6th Annual International Congress of Myology, March 25-28, 2019, Bordeaux, France.
Evaluation of safety and efficacy of BIO101, a new investigational drug for Sarcopenia: a double-blind, placebo controlled, randomized clinical trial. Dioh et al. Oral presentation at 10th International Conference on Frailty & Sarcopenia Research (ICFSR), February 20-22, 2019, Miami, USA.
Abstract in press in The Journal of Frailty & Aging.
Designing a clinical program for BIO101, a Mas receptor activator to target Age-related sarcopenia. Dioh et al. Oral presentation at 10th International Conference on Frailty & Sarcopenia Research (ICFSR), February 20-22, 2019, Miami, USA.
The MYODA Operational Seamless clinical trial design phase I to III: A new approach for Rare Diseases to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of BIO101 (MAS Activator) in Pediatric Patients with a Genetically Confirmed Diagnosis of Duchenne Muscular Dystrophy (DMD). Chabane et al. Poster presentation at 24th WMS Congress, 1-5th Oct, Copenhagen, Denmark
Abstract published in Neuromuscular Disorders, 29, S1, S92, abstract P149
MYODA clinical program: Composite score for assessing the efficacy of BIO101 (MAS activator) in ambulatory and non-ambulatory Duchenne boys. Chabane et al. Poster presentation at 24th WMS Congress, 1-5th Oct, Copenhagen, Denmark
Abstract published in Neuromuscular Disorders, 29, S1, S178, abstract EP87
The MYODA seamless clinical trial design: a true innovation for rare diseases including DMD. Chabane et al. Poster presentation at Myology 2019, March 25-28th, Bordeaux, France. Abstract 460
In vivo effects of Sarconeos (API BIO101) on mouse model of severe spinal muscular atrophy. Belzier et al. Poster presentation at the 6th Annual International Congress of Myology, March 25-28, 2019, Bordeaux, France.
MYODA clinical program: A new approach unravelling drug effects through a composite outcome score encompassing ambulant to non-ambulant disease stages. Chabane et al. Poster presentation at Myology 2019, March 25-28th, Bordeaux, France. Abstract 459
SARCONEOS (API BIO101) targets Mas receptor within the protective arm of the renin angiotensin system and proves efficacy in various models of muscle wasting. Dilda et al. Oral presentation at 10th International Conference on Frailty & Sarcopenia Research (ICFSR), February 20-22, 2019, Miami, USA.
Abstract in press in The Journal of Frailty & Aging, , 8 (S1), S14, abstract OC10
BIO101 demonstrates combined beneficial effects on skeletal muscle and respiratory functions in a mouse model of Duchenne muscular dystrophy. Dilda et al. Poster presentation at 24th WMS Congress, 1-5th Oct, Copenhagen, Denmark
Abstract published in Neuromuscular Disorders, 29, S1, S158, abstract P311
BIO101 demonstrates combined beneficial effects on muscle and motor neurons in a mouse model of severe spinal muscular atrophy. Latil et al. Poster presentation at 24th WMS Congress, 1-5th Oct, Copenhagen, Denmark.
Abstract published in Neuromuscular Disorders, 29, S1, S189, abstract P370
Preclinical characterization of Sarconeos (API BIO101) in Duchenne muscular dystrophy. Latil et al. Poster presentation at Myology 2019, March 25-28th, Bordeaux, France. Abstract 351
In vivo effects of Sarconeos (API BIO101) on mouse model of severe spinal muscular atrophy. Bézier et al. Poster presentation at Myology 2019, March 25-28th, Bordeaux, France. Abstract 277